{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:10:32Z","timestamp":1790079032039,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11864-020-0718-2","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T07:02:57Z","timestamp":1586242977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Oncolytic Viruses for the Treatment of Metastatic Melanoma"],"prefix":"10.1007","volume":"21","author":[{"given":"Megan H.","family":"Trager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa J.","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M.","family":"Saenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"issue":"1","key":"718_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"718_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2010.09.007","volume":"20","author":"PV Dickson","year":"2011","unstructured":"Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):1\u201317. https:\/\/doi.org\/10.1016\/j.soc.2010.09.007.","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"718_CR3","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/jid.2014.452","volume":"135","author":"DC Whiteman","year":"2015","unstructured":"Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (\u22641\u2009mm) than from thick melanomas (>4\u2009mm) in Queensland, Australia. J Investig Dermatol. 2015;135(4):1190\u20133. https:\/\/doi.org\/10.1038\/jid.2014.452.","journal-title":"J Investig Dermatol"},{"key":"718_CR4","first-page":"1705","volume":"2016","author":"A Pay","year":"2016","unstructured":"Pay A. Malignant melanoma (non-metastatic): sentinel lymph node biopsy. BMJ Clin Evid. 2016;2016:1705.","journal-title":"BMJ Clin Evid"},{"issue":"16","key":"718_CR5","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/jco.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635\u201348. https:\/\/doi.org\/10.1200\/jco.2001.19.16.3635.","journal-title":"J Clin Oncol"},{"issue":"6","key":"718_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","journal-title":"CA Cancer J Clin"},{"key":"718_CR7","doi-asserted-by":"publisher","unstructured":"Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg (Chicago, Ill : 1960). 2004;139(9):961\u20136; discussion 6-7. https:\/\/doi.org\/10.1001\/archsurg.139.9.961.","DOI":"10.1001\/archsurg.139.9.961"},{"issue":"4","key":"718_CR8","first-page":"572","volume":"7","author":"A Sandru","year":"2014","unstructured":"Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7(4):572\u20136.","journal-title":"J Med Life"},{"issue":"4","key":"718_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2217\/fvl-2016-0129","volume":"12","author":"J Maroun","year":"2017","unstructured":"Maroun J, Munoz-Alia M, Ammayappan A, Schulze A, Peng KW, Russell S. Designing and building oncolytic viruses. Futur Virol. 2017;12(4):193\u2013213. https:\/\/doi.org\/10.2217\/fvl-2016-0129.","journal-title":"Futur Virol"},{"key":"718_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fonc.2014.00074","volume":"4","author":"ZS Guo","year":"2014","unstructured":"Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014;4:74. https:\/\/doi.org\/10.3389\/fonc.2014.00074.","journal-title":"Front Oncol"},{"key":"718_CR11","doi-asserted-by":"publisher","first-page":"197675","DOI":"10.1016\/j.virusres.2019.197675","volume":"270","author":"LQ Fu","year":"2019","unstructured":"Fu LQ, Wang SB, Cai MH, Wang XJ, Chen JY, Tong XM, et al. Recent advances in oncolytic virus-based cancer therapy. Virus Res. 2019;270:197675. https:\/\/doi.org\/10.1016\/j.virusres.2019.197675.","journal-title":"Virus Res"},{"issue":"5007","key":"718_CR12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","volume":"252","author":"RL Martuza","year":"1991","unstructured":"Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (New York, NY). 1991;252(5007):854\u20136. https:\/\/doi.org\/10.1126\/science.1851332.","journal-title":"Science (New York, NY)"},{"issue":"10","key":"718_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11912-018-0729-3","volume":"20","author":"CY Bayan","year":"2018","unstructured":"Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, et al. The role of oncolytic viruses in the treatment of melanoma. Curr Oncol Rep. 2018;20(10):80. https:\/\/doi.org\/10.1007\/s11912-018-0729-3.","journal-title":"Curr Oncol Rep"},{"issue":"22","key":"718_CR14","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1158\/1078-0432.Ccr-06-0759","volume":"12","author":"JC Hu","year":"2006","unstructured":"Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737\u201347. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-0759.","journal-title":"Clin Cancer Res"},{"issue":"34","key":"718_CR15","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/jco.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763\u201371. https:\/\/doi.org\/10.1200\/jco.2009.24.3675.","journal-title":"J Clin Oncol"},{"issue":"1","key":"718_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"A RHI","year":"2019","unstructured":"\u2022\u2022 RHI A, Collichio F, Harrington KJ, Middleton MR, Downey G, \u04e6hrling K, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J Immunother Cancer. 2019;7(1):145. https:\/\/doi.org\/10.1186\/s40425-019-0623-z This was a large phase III trial that compared T-VEC to GM-CSF. It showed that T-VEC resulted in improved longer-term efficacy compared to GM-CSF and was well tolerated.","journal-title":"J Immunother Cancer"},{"issue":"25","key":"718_CR17","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/jco.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20138. https:\/\/doi.org\/10.1200\/jco.2014.58.3377.","journal-title":"J Clin Oncol"},{"key":"718_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-015-0063-3","volume":"3","author":"FJ Kohlhapp","year":"2015","unstructured":"Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer. 2015;3:18. https:\/\/doi.org\/10.1186\/s40425-015-0063-3.","journal-title":"J Immunother Cancer"},{"issue":"22","key":"718_CR19","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/jco.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"\u2022\u2022 Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619\u201326. https:\/\/doi.org\/10.1200\/jco.2016.67.1529 This was an open-label multicenter phase 1b trial of T-VEC in combination with ipiimumab. It howed that the combination therapy had a tolerable safety profile and the combination provided greater efficacy than monotherapy.","journal-title":"J Clin Oncol"},{"issue":"17","key":"718_CR20","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/jco.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"\u2022\u2022 Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658\u201367. https:\/\/doi.org\/10.1200\/jco.2017.73.7379 This was a phase II trial examining the results of combination T-VEC and immunotherapy with ipilimumab. It showed that combination therapy had a higher objective response rate without additional safety concerns.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"718_CR21","doi-asserted-by":"publisher","first-page":"9568","DOI":"10.1200\/JCO.2016.34.15_suppl.9568","volume":"34","author":"GV Long","year":"2016","unstructured":"\u2022\u2022 Long GV, Dummer R, Ribas A, Puzanov I, Vander Walde A, Andtbacka RHI, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(15_suppl):9568. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.9568 This phase Ib clinical trial showed that combination therapy with pembrolizumab and T-VEC led to clinical benefit in advanced melanoma. A phase III trial is currently underway.","journal-title":"J Clin Oncol"},{"issue":"1","key":"718_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-018-0337-7","volume":"6","author":"L Sun","year":"2018","unstructured":"Sun L, Funchain P, Song JM, Rayman P, Tannenbaum C, Ko J, et al. Talimogene laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. J Immunother Cancer. 2018;6(1):36. https:\/\/doi.org\/10.1186\/s40425-018-0337-7.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"718_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1053\/sder.2003.50005","volume":"22","author":"L Geskin","year":"2003","unstructured":"Geskin L, Brown CR, Kirkwood JM. Adjuvant therapy of melanoma. Semin Cutan Med Surg. 2003;22(1):55\u201367.","journal-title":"Semin Cutan Med Surg"},{"issue":"15_suppl","key":"718_CR24","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2018.36.15_suppl.9508","volume":"36","author":"RHI Andtbacka","year":"2018","unstructured":"Andtbacka RHI, Dummer R, Gyorki DE, Berger AC, Conry RM, Demidov LV, et al. Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL). J Clin Oncol. 2018;36(15_suppl):9508. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.9508.","journal-title":"J Clin Oncol"},{"key":"718_CR25","doi-asserted-by":"crossref","unstructured":"Reinhard Dummer DEG, John Robert Hyngstrom, Adam C. Berger, Robert Martin Conry, Lev V. Demidov, Anjali Sharma, Sheryl Treichel, Mark B. Faries, Merrick I. Ross; Department of Dermatology, University Hospital Z\u00fcrich Skin Cancer Center, Z\u00fcrich, Switzerland; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Univ of Utah, Salt Lake City, UT; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; The Kirkland Clinic at Acton Road, Birmingham, AL; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Kaiser Permanente, Oakland, CA; Amgen, Inc., South San Francisco, CA; John Wayne Cancer Institute, Santa Monica, CA; The University of Texas MD Anderson Cancer Center, Houston, TX. One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL). 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.9520"},{"issue":"12","key":"718_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/14712598.2018.1544614","volume":"18","author":"LD Rothermel","year":"2018","unstructured":"Rothermel LD, Zager JS. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next? Expert Opin Biol Ther. 2018;18(12):1199\u2013207. https:\/\/doi.org\/10.1080\/14712598.2018.1544614.","journal-title":"Expert Opin Biol Ther"},{"issue":"20","key":"718_CR27","first-page":"4927","volume":"53","author":"T Kageshita","year":"1993","unstructured":"Kageshita T, Yoshii A, Kimura T, Kuriya N, Ono T, Tsujisaki M, et al. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res. 1993;53(20):4927\u201332.","journal-title":"Cancer Res"},{"issue":"15_suppl","key":"718_CR28","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1200\/jco.2015.33.15_suppl.9030","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Curti BD, Kaufman H, Daniels GA, Nemunaitis JJ, Spitler LE, et al. Final data from CALM: a phase II study of coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. J Clin Oncol. 2015;33(15_suppl):9030. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.9030.","journal-title":"J Clin Oncol"},{"key":"718_CR29","doi-asserted-by":"publisher","unstructured":"Curti B, Richards J, Faries M, Andtbacka RHI, Grose M, Karpathy R, et al. The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma. Ann Oncol. 2016;27(suppl_6). https:\/\/doi.org\/10.1093\/annonc\/mdw378.06.","DOI":"10.1093\/annonc\/mdw378.06"},{"issue":"15_suppl","key":"718_CR30","doi-asserted-by":"publisher","first-page":"TPS3108","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3108","volume":"35","author":"HS Pandha","year":"2017","unstructured":"Pandha HS, Ralph C, Harrington K, Curti BD, Sanborn RE, Akerley WL, et al. Keynote-200 phase 1b: a novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients. J Clin Oncol. 2017;35(15_suppl):TPS3108\u2013TPS. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.TPS3108.","journal-title":"J Clin Oncol"},{"key":"718_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fonc.2017.00149","volume":"7","author":"IR Eissa","year":"2017","unstructured":"Eissa IR, Naoe Y, Bustos-Villalobos I, Ichinose T, Tanaka M, Zhiwen W, et al. Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials. Front Oncol. 2017;7:149. https:\/\/doi.org\/10.3389\/fonc.2017.00149.","journal-title":"Front Oncol"},{"issue":"4","key":"718_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/cgt.2011.80","volume":"19","author":"TT Sahin","year":"2012","unstructured":"Sahin TT, Kasuya H, Nomura N, Shikano T, Yamamura K, Gewen T, et al. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer. Cancer Gene Ther. 2012;19(4):229\u201337. https:\/\/doi.org\/10.1038\/cgt.2011.80.","journal-title":"Cancer Gene Ther"},{"issue":"15_suppl","key":"718_CR33","doi-asserted-by":"publisher","first-page":"9510","DOI":"10.1200\/JCO.2017.35.15_suppl.9510","volume":"35","author":"RHI Andtbacka","year":"2017","unstructured":"Andtbacka RHI, Ross MI, Agarwala SS, Taylor MH, Vetto JT, Neves RI, et al. Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma. J Clin Oncol. 2017;35(15_suppl):9510. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9510.","journal-title":"J Clin Oncol"},{"issue":"2","key":"718_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/mt.2009.262","volume":"18","author":"J Nemunaitis","year":"2010","unstructured":"Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 2010;18(2):429\u201334. https:\/\/doi.org\/10.1038\/mt.2009.262.","journal-title":"Mol Ther"},{"issue":"21","key":"718_CR35","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.Ccr-08-0524","volume":"14","author":"L Vidal","year":"2008","unstructured":"Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008;14(21):7127\u201337. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-0524.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"718_CR36","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/mt.2012.146","volume":"20","author":"E Galanis","year":"2012","unstructured":"Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, et al. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-Dearing strain) in patients with metastatic melanoma. Mol Ther. 2012;20(10):1998\u20132003. https:\/\/doi.org\/10.1038\/mt.2012.146.","journal-title":"Mol Ther"},{"issue":"4","key":"718_CR37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","volume":"79","author":"D Mahalingam","year":"2017","unstructured":"Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, et al. A phase II study of REOLYSIN((R)) (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2017;79(4):697\u2013703. https:\/\/doi.org\/10.1007\/s00280-017-3260-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"718_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/cncr.21611","volume":"106","author":"RD Rao","year":"2006","unstructured":"Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106(2):375\u201382. https:\/\/doi.org\/10.1002\/cncr.21611.","journal-title":"Cancer."},{"issue":"5","key":"718_CR39","first-page":"540","volume":"38","author":"LS Glinkina","year":"1992","unstructured":"Glinkina LS, Bruvere R, Venskus DR, Garklava RR, Muceniece AJ. The cellular immunity indices of patients with malignant melanoma using the viral immunomodulator Rigvir. Vopr Onkol. 1992;38(5):540\u20137.","journal-title":"Vopr Onkol"},{"issue":"5","key":"718_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/CMR.0000000000000180","volume":"25","author":"S Doni\u0146a","year":"2015","unstructured":"Doni\u0146a S, Str\u0113le I, Proboka G, Auzi\u0146\u0161 J, Alberts P, Jonsson B, et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25(5):421\u20136. https:\/\/doi.org\/10.1097\/CMR.0000000000000180.","journal-title":"Melanoma Res"},{"key":"718_CR41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3389\/fonc.2019.00436","volume":"9","author":"X Shao","year":"2019","unstructured":"Shao X, Wang X, Guo X, Jiang K, Ye T, Chen J, et al. STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells. Front Oncol. 2019;9:436. https:\/\/doi.org\/10.3389\/fonc.2019.00436.","journal-title":"Front Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-0718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-020-0718-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-0718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T01:22:25Z","timestamp":1616116945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-020-0718-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["718"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-0718-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]},"assertion":[{"value":"19 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Megan H. Trager declares that she has no conflict of interest.Larisa J. Geskin has received research funding from Helsinn Therapeutics, Mallinckrodt, Medivir, Soligenix, and Kyowa Hakko Kirin and has received compensation from Helsinn Therapeutics, Mallinckrodt, Medivir, and Therakos for service as a consultant.Yvonne M. Saenger has received research funding for clinical and laboratory research from Amgen and has a patent on immune signatures for melanoma recurrence pending.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"26"}}